IDEXX Laboratories, Inc. $IDXX Stock Position Raised by Rakuten Investment Management Inc.

Rakuten Investment Management Inc. lifted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 10.2% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 20,981 shares of the company’s stock after buying an additional 1,945 shares during the quarter. Rakuten Investment Management Inc.’s holdings in IDEXX Laboratories were worth $11,192,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. J.Safra Asset Management Corp purchased a new stake in shares of IDEXX Laboratories in the second quarter valued at $25,000. Elevation Wealth Partners LLC grew its holdings in shares of IDEXX Laboratories by 188.2% during the second quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock worth $26,000 after buying an additional 32 shares in the last quarter. Pension & Wealth Management Advisors Inc. acquired a new position in shares of IDEXX Laboratories in the third quarter valued at approximately $29,000. Arlington Trust Co LLC boosted its position in IDEXX Laboratories by 46.3% during the second quarter. Arlington Trust Co LLC now owns 60 shares of the company’s stock worth $32,000 after acquiring an additional 19 shares during the last quarter. Finally, Bell Investment Advisors Inc boosted its position in IDEXX Laboratories by 45.5% during the third quarter. Bell Investment Advisors Inc now owns 64 shares of the company’s stock worth $33,000 after acquiring an additional 20 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, Director Lawrence D. Kingsley sold 2,203 shares of the business’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $532.08, for a total value of $1,172,172.24. Following the sale, the director directly owned 9,568 shares in the company, valued at approximately $5,090,941.44. The trade was a 18.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.79% of the company’s stock.

Trending Headlines about IDEXX Laboratories

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: IDEXX reported Q3 adjusted EPS of $3.96, above the $3.71 consensus, and revenue of $1.21 billion, ahead of expectations. The company also raised its FY2026 EPS guidance to $14.96–$15.16, versus analysts’ prior $14.86 estimate; its $4.7–$4.8 billion revenue outlook is broadly in line with consensus. IDEXX Q3 beat and raised outlook
• Positive Sentiment: UBS said the company delivered strong results despite a lackluster veterinary-visit backdrop, suggesting execution and demand for its offerings remain resilient. UBS comments on IDEXX results
• Positive Sentiment: Morgan Stanley maintained an overweight rating and raised its price target to $810, signaling continued analyst confidence in the shares.
• Neutral Sentiment: One Seeking Alpha analysis characterized IDEXX’s Q3 performance as best-in-class, while another downgraded the stock, arguing that its valuation is too high. The mixed assessments leave valuation as a key consideration after the rally. Valuation-focused downgrade

Analyst Ratings Changes

Several equities research analysts have recently issued reports on IDXX shares. Citigroup raised their price objective on IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a report on Wednesday, August 5th. KeyCorp started coverage on shares of IDEXX Laboratories in a research report on Monday, October 12th. They set a “sector weight” rating on the stock. BTIG Research dropped coverage on IDEXX Laboratories in a research report on Friday, October 30th. They set a “buy” rating on the stock. Leerink Partners lowered their target price on IDEXX Laboratories from $725.00 to $715.00 and set an “outperform” rating for the company in a research note on Monday, July 13th. Finally, Barclays dropped their price objective on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a report on Tuesday, August 11th. Seven research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, IDEXX Laboratories currently has an average rating of “Moderate Buy” and a consensus target price of $719.55.

IDEXX Laboratories Price Performance

Shares of IDXX opened at $698.55 on Thursday. IDEXX Laboratories, Inc. has a 12 month low of $500.61 and a 12 month high of $769.98. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.19 and a quick ratio of 0.87. The stock has a fifty day moving average price of $541.78 and a 200 day moving average price of $573.62. The company has a market cap of $55.04 billion, a P/E ratio of 45.41 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Monday, November 2nd. The company reported $3.96 EPS for the quarter, beating the consensus estimate of $3.71 by $0.25. The company had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.19 billion. IDEXX Laboratories had a net margin of 25.36% and a return on equity of 71.04%. IDEXX Laboratories’s revenue was up 9.9% compared to the same quarter last year. During the same quarter last year, the business earned $3.22 earnings per share. On average, research analysts forecast that IDEXX Laboratories, Inc. will post 15.06 earnings per share for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.